USA - NASDAQ:MLAB - US59064R1095 - Common Stock
The current stock price of MLAB is 73.94 USD. In the past month the price increased by 1.18%. In the past year, price decreased by -27.82%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.84 | 218.53B | ||
| DHR | DANAHER CORP | 28.69 | 158.40B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 161.67 | 49.06B | ||
| A | AGILENT TECHNOLOGIES INC | 26.94 | 41.62B | ||
| IQV | IQVIA HOLDINGS INC | 18.97 | 37.50B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.53 | 28.90B | ||
| WAT | WATERS CORP | 29.87 | 22.58B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 36.97 | 18.79B | ||
| ILMN | ILLUMINA INC | 27.68 | 18.55B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.27 | 16.58B | ||
| TEM | TEMPUS AI INC | N/A | 11.90B | ||
| RVTY | REVVITY INC | 19.36 | 10.76B |
Mesa Laboratories, Inc. engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. The company is headquartered in Lakewood, Colorado and currently employs 730 full-time employees. The firm's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.
MESA LABORATORIES INC
12100 W 6th Ave
Lakewood COLORADO 80228 US
CEO: Gary M. Owens
Employees: 730
Phone: 13039878000
Mesa Laboratories, Inc. engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. The company is headquartered in Lakewood, Colorado and currently employs 730 full-time employees. The firm's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.
The current stock price of MLAB is 73.94 USD. The price decreased by -2.53% in the last trading session.
MESA LABORATORIES INC (MLAB) has a dividend yield of 0.84%. The yearly dividend amount is currently 0.64.
MLAB has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
9 analysts have analysed MLAB and the average price target is 90.27 USD. This implies a price increase of 22.09% is expected in the next year compared to the current price of 73.94.
MESA LABORATORIES INC (MLAB) will report earnings on 2026-02-02.
You can find the ownership structure of MESA LABORATORIES INC (MLAB) on the Ownership tab.
ChartMill assigns a technical rating of 3 / 10 to MLAB. When comparing the yearly performance of all stocks, MLAB is a bad performer in the overall market: 77.52% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to MLAB. MLAB has a medium profitability rating, but doesn't score so well on its financial health evaluation.
Over the last trailing twelve months MLAB reported a non-GAAP Earnings per Share(EPS) of -0.27. The EPS decreased by -104.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.14% | ||
| ROE | -0.36% | ||
| Debt/Equity | 0.46 |
9 analysts have analysed MLAB and the average price target is 90.27 USD. This implies a price increase of 22.09% is expected in the next year compared to the current price of 73.94.
For the next year, analysts expect an EPS growth of 2471.86% and a revenue growth 3.51% for MLAB